Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets
Tessa Y.S. Le Large, … , Elisa Giovannetti, Maarten F. Bijlsma
Tessa Y.S. Le Large, … , Elisa Giovannetti, Maarten F. Bijlsma
Published July 7, 2020
Citation Information: JCI Insight. 2020;5(15):e138290. https://doi.org/10.1172/jci.insight.138290.
View: Text | PDF
Research Article Cell biology Oncology

Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by a relative paucity of cancer cells that are surrounded by an abundance of nontumor cells and extracellular matrix, known as stroma. The interaction between stroma and cancer cells contributes to poor outcome, but how proteins from these individual compartments drive aggressive tumor behavior is not known. Here, we report the proteomic analysis of laser-capture microdissected (LCM) PDAC samples. We isolated stroma, tumor, and bulk samples from a cohort with long- and short-term survivors. Compartment-specific proteins were measured by mass spectrometry, yielding what we believe to be the largest PDAC proteome landscape to date. These analyses revealed that, in bulk analysis, tumor-derived proteins were typically masked and that LCM was required to reveal biology and prognostic markers. We validated tumor CALB2 and stromal COL11A1 expression as compartment-specific prognostic markers. We identified and functionally addressed the contributions of the tumor cell receptor EPHA2 to tumor cell viability and motility, underscoring the value of compartment-specific protein analysis in PDAC.

Authors

Tessa Y.S. Le Large, Giulia Mantini, Laura L. Meijer, Thang V. Pham, Niccola Funel, Nicole C.T. van Grieken, Bart Kok, Jaco Knol, Hanneke W.M. van Laarhoven, Sander R. Piersma, Connie R. Jimenez, G. Kazemier, Elisa Giovannetti, Maarten F. Bijlsma

×

Figure 5

EPHA2 phosphorylation in PDAC cells conveys sensitivity to the inhibitor ALW-II-27.

Options: View larger image (or click on image) Download as PowerPoint
EPHA2 phosphorylation in PDAC cells conveys sensitivity to the inhibitor...
(A) Differential expression of EPHA2 between bulk (n = 16) and isolated epithelial compartments (n = 15) identified EPHA2 as specifically but heterogeneously expressed in the tumor compartment (limma test, corrected for multiple testing, P = 0.05) (mean ± SD). (B) Reduction of EPHA2 expression by shRNA in Capan-2 cells significantly reduced proliferation rate (P < 0.001, unpaired 2-way t test) (mean ± SEM) (n = 7). (C) Dose-response curves of cell lines treated with ALW-II-27. (D) Western blot analysis of cells after treatment with ALW-II-27 shows reduction of EPHA2 expression and phosphorylation of activation site pY-588. See complete unedited blots in the supplemental material. (E) Transwell migration of Capan-2 cells was reduced upon pretreatment with 1 μM ALW-II-27, irrespectively of attractant (EGF, P = 0.0005, FCS P = 0.0029, 2-tailed t test with Welch’s correction) (mean ± SEM) (n = 3).

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts